Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer

Statement of clinical relevance:
In spite of diagnosis and treatment improvements, lung cancer is the leading cause of death from cancer with a 10 years overall survival less than 10%. Although surgical resection of lung tumors restricted to the chest is in many cases the most effective method to control the disease, it might not be sufficient or curative for a proportion of patients with stage I NSCLC as inferred from 30% death within 5 years after surgery. The use of adjuvant chemotherapy is still a matter of debate for these patients. Several highthrouput analyses have suggested that stage I NSCLC might represent heterogeneous prognostic subgroups. In this study, by using a simple immunohistochemical approach with a specific antibody, we demonstrate that the status of histone H4K20 trimethylation stratifies patients with stage I adenocarcinoma tumors for risk of cancer death. Therefore, studying H4K20me3 status might represent a useful genomic tool to identify prognostic subgroups of stage I patients that could justify the use of adjuvant chemotherapy.
Abstract
Purpose: Epigenetic modifications of Histones have crucial roles in the control of gene activity, nuclear architecture and genomic stability. In this respect they may contribute to the development and progression of cancer. We investigated whether epigenetic changes of histone H4 are involved in lung carcinogenesis.
Experimental design: Epigenetic modifications of histone H4 were studied by immunohistochemistry (IHC) in normal lung and 157 lung carcinoma using antibodies specifically recognizing the acetylated (Ac) lysines 5 (K5), K8, K12, K16 and trimethylated (me3) K20 residues of histone H4. Western blotting was used to validate the IHC results.
H4K20me3 was also studied in 17 preneoplastic lesions. Expression of the Suv4-20h1/2 trimethyltransferases was analyzed by quantitative RT/PCR in a subset of tumor samples.
Results: As compared to normal lung, cancer cells displayed an aberrant pattern of histone H4 modifications with hyperacetylation of H4K5/K8, hypoacetylation of H4K12/K16 and loss of H4K20 trimethylation. Alteration of H4K20 trimethylation was frequent in squamous cell carcinoma (67%) and was observed in early precursors lesions in which the level of H4K20me3 staining strongly decreased with disease progression. In adenocarcinoma, the downregulation of H4K20me3 was less frequent (28%) but allowed the identification of a subgroup of stage I adenocarcinoma patients with reduced survival (p=0.007). Loss of H4K20 trimethylation was associated with decreased expression of Suv4-20h2, a specific H4K20 trimethyltransferase involved in telomere length maintenance.
Conclusions:
Our findings indicate an important role of histone H4 modifications in bronchial carcinogenesis and highlight H4K20me3 as a candidate biomarker for early detection and therapeutic approaches of lung cancer.
Introduction
Lung cancer is the leading cause of death from cancer among males in Europe and both men and women in the USA. Non-small-cell lung cancer (NSCLC) accounts for almost 80 percent of such deaths (1) (2) (3) . In spite of diagnosis and treatment improvements, 10 years overall lung cancer survival is less than 10%, claiming more deaths than breast, colon and prostate cancers all together. Early diagnosis allowing surgical resection with a 60 to 80% 5 years survival is performed in only less than 25% of the patients. Therefore, the identification of the molecular biomarkers of clonal selection in lung cancer as well as the comprehension of the mechanisms of their participation to the lung carcinogenesis process are required to establish the prognostic factors of progression of preneoplastic and invasive tumors towards earlier diagnosis, and to define more efficient therapies with lower side effects.
Lung cancer is the end result of a process that associates multifocal morphological transformation and multistep accumulation of molecular abnormalities (4) . The clonal selection leading to proliferation and invasion is achieved by disruption of the cell growth controls, with a tumor progression kinetic depending on the number and accumulation rate of these molecular alterations. Common genetic abnormalities in lung carcinogenesis include invalidation of tumor suppressor genes, activation of oncogenes and chromosomal abnormalities (5) . Furthermore, it is now apparent that epigenetic modifications that do not affect the primary sequence of the DNA also contribute to lung tumor formation. These involve both global genomic hypomethylation leading to chromosomal instability, and regional hypermethylation at certain promoters (6) (7) (8) . By this mechanism of silencing, the expression of tumor suppressor genes in the cancer cell can be reduced or eliminated as an alternative mechanism to genetic mutation. Chromatin modifications represent another mechanism of epigenetic regulation. They occur at the level of histones that are the targets for several post-translational covalent modifications which allow regulable contacts with the underlying DNA and thus affect higher-order chromatin structures (9) . In this regard, histone covalent modifications influence a multitude of cellular processes (10-12) and aberrant histone acetylation and methylation patterns were recently reported in human tumors (13, 14) .
Histone H4 is one of the nucleosomal core histones. Acetylation and methylation of lysine residues in its N-terminal tail have been reported to affect higher-order chromatin structure, transcriptional regulation and DNA repair, suggesting that alteration of these histone marks might play a role in tumorigenesis (12) . Accordingly, loss of lysine 16 acetylation and lysine 20 trimethylation has been recently shown in cancer cells from liver, breast and colon as well as in lymphoma (1, 14, 15) . The aim of this study was to analyze the role of histone H4 modifications in lung cancer. We examined the acetylation and methylation pattern of histone H4 in human normal lung and non small cell lung cancer by using immunohistochemistry and specific antibodies, and analyzed the relationships with clinico-parameters and clinical outcome. Our results demonstrate a global distorted pattern of histone H4 modifications in lung tumors and provide evidence that loss of H4K20 trimethylation plays a crucial role in lung tumorigenesis. H4K5Ac/K8Ac/K12Ac/K16Ac/K20me3 on serial sections of 3 microns intervals, as well as on tumor blots. Reproducibility of staining was validated in 10 cases stained at several days interval times : the variability between the two score assessments by pathologists was less than 10% of global score. Scores of staining were ascribed to each case and antibody by multiplying the percentage of positive cells (0 to 100%) by the staining intensity (0, null; 1, faint; 2, moderate; 3, strong). They ranged from 0 to 300. Normal bronchi and alveolar epithelial cells were used as positive internal controls. These normal structures exhibited low staining scores for acetylated H4K5/K8 (20 and 40 respectively) and high staining scores for acetylated H4K12/16 and trimethylated H4K20 (300, 240 and 250 respectively).
Materials and methods
Patients and tissue samples
Immunoblotting
Immunoblotting was performed on 15 representative tumor samples and their matched normal lung tissues. Proteins were extracted from sections taken at the immediate vicinity of those studied by immunohistochemistry. Immunoblotting experiments were performed as previously described (18) with the same antibodies used for immunohistochemistry. Dilutions of the primary antibodies were 1:500 for acetylated H4K5 and 1/1000 for acetylated H4K8/K12/K16 and trimethylated H4K20 antibodies. To ensure equal loading and transfer of proteins, the membranes were subsequently probed with a polyclonal actin antibody (1:500;
Sigma-Aldrich; L'Isle d'Abeau). 
RT-QPCR
Results
Global modification of histone H4 acetylation in lung cancer
One hundred non small cell lung cancers comprising 50 squamous carcinoma and 50 adenocarcinoma were analyzed by immunohistochemistry (IHC) using antibodies specifically recognizing the acetylated (Ac) lysines 5 (K5), K8, K12 or K16 residues of histone H4. Low levels of nuclear H4K5Ac and H4K8Ac staining were found in normal lung parenchyma adjacent to or distant from tumor bulk, whereas high levels of immunostaining were observed for H4K12Ac and H4K16Ac (Figure 1 and supplementary Figure 1 ). Therefore, these data
show that the lysine residues of the H4 tail exhibit a differential pattern of acetylation in the normal lung.
As compared to normal lung parenchyma, the study of lung tumors revealed a general increase of H4K5Ac/K8Ac expression ( Figure 1 A strong association between H4K5Ac and H4K8Ac (Spearmann's correlation coefficient, r=0,409; p<0.0001) or H4K5Ac and H4K12AC (Spearmann's correlation coefficient, r=0,347; p=0.0007) was also found independently of the histological type. The significance of these correlations is still unclear but could reflect a thorough crosstalk between histone H4 modifications as recently described for histone H3 (19, 20) . No additional significant relationships were observed between H4K5/K8/K12/K16Ac stainings and clinico-parameters (stage, clinical outcome).
Loss of trimethylation at H4K20 in lung tumors.
The same series of lung carcinoma was studied for histone H4 lysine 20 trimethylation (H4K20me3) by immunohistochemistry using a specific anti-trimethylated K20 antibody. As shown in Figure 3A , a global loss of H4K20me3 was observed in lung tumors (panel b) as compared to normal lung that expressed strong H4K20me3 staining (panel a). These results were confirmed by western blotting in representative cases ( Figure 3B ). The distribution of H4K20me3 staining scores showed that 70% of the tumor samples had a H4K20me3 score between 0 and 100 ( Figure 3C ). As the mean score of the normal lung was 250, it can be stated that trimethylation of H4K20 is frequently and strongly decreased in lung tumors.
Strikingly, loss of H4K20me3 was more frequent in squamous carcinoma than in adenocarcinoma ( Figure 3D , Mann Whitney, p<0.0001). Moreover, a strong inverse association between H4K8Ac and H4K20me3 modifications was detected in adenocarcinoma (Spearmann's correlation coefficient, r=-0.487; p=0.0008).
Trimethylation at H4K20 is lost in squamous preneoplasia.
Trimethylation of H4K20 was strongly downregulated in squamous carcinoma as revealed by the distribution of H4K20me3 scores (67% of cases with a score <60, Figure 3D and 4A). In these tumors, no relationship was observed between H4K20me3 IHC status and stage or clinical outcome but we noticed that a large proportion (69%) of stage I tumor CIS. As compared to normal bronchial epithelium in which basal cells exhibited a strong nuclear staining, we noticed that hyperplasia displayed a less intense H4K20me3
immunostaining with the appearance of some negative nuclei. Strikingly, the level of H4K20me3 strongly decreased with disease progression from cell hyperplasia to metaplasia, dysplasia (mild, moderate, severe) and then to CIS (Figure 4 , B and C). Therefore, these results demonstrate that trimethylation of H4K20 is lost in early precursors lesions of squamous cell carcinoma.
Loss of H4K20me3 correlates with a poor survival in stage I adenocarcinoma patients
In contrast with squamous cell carcinoma, the downregulation of H4K20me3 was less frequent in adenocarcinoma (28% of cases with a score <60, Figure 3D ). Interestingly, the distribution of H4K20me3 scores clearly identified two populations of stage I adenocarcinoma tumor samples with distinct clinical outcome, a longer cancer related survival being observed for patients whose tumors expressed higher levels (score > 100) ( Figure 5A, p=0 .0125). To validate the prognostic power of H4K20me3 in early stage adenocarcinoma, we studied H4K20me3 immunostaining in another set of stage I adenocarcinoma. Analysis of these new series of 57 stage I adenocarcinoma samples confirmed the existence of two distinct H4K20me3 staining groups ( Figure 5B ). According to 
Loss of Suvar4-20h2 expression correlates with reduced H4K20me3
Mechanistic basis of H4K20me3 modification may be related to altered expression of various histone-modifying enzymes. Enzymes that demethylate H4K20 have not yet been identified. By contrast, it is well-known that trimethylation of histone H4 lysine 20 is catalysed by the histone methyltransferases (HMTases) Suv4-20h1/2 (also called KMT5B/C) (22) . To uncover the mechanisms involved in H4K20me3 deregulation in lung tumors, we transcripts respectively as compared to normal lung (Table 1) , thereby indicating that expression of Suv4-20h transcripts is globally downregulated in lung tumors. Importantly, we observed that low levels of H4K20me3 were associated with a decrease of Suv4-20h2 transcripts (p=0.019). By contrast, no significant association was found between H4K20me3 staining and Suv4-20h1 mRNA level (p=0.37). Altogether these results suggest that alteration of Suv4-20h2 expression might play a role in the deregulation of H4K20 trimethylation in lung tumors.
Discussion
The prognosis of lung cancer is affected by the difficulties of diagnosing early stage disease amenable to surgery. Thus, novel diagnostic, risk assessment and therapeutic approaches are urgently needed for this common and devastating cancer. Epigenetic has become an increasingly important aspect of cancer biology. Epigenetic changes encompasse an array of molecular modifications to both DNA and chromatin, the most extensively investigated of which is DNA methylation. Recently, aberrant histone acetylation and methylation patterns have been reported in tumors (13, 14) , suggesting that perturbation in chromatin structure may also contribute to tumorigenesis. In this study, we show that lung tumors exhibit an altered pattern of histone H4 modifications as compared to normal lung.
Furthermore, we demonstrate that trimethylation at lysine 20 of histone H4 is dramatically reduced in squamous preneoplastic lesions and provide evidence that loss of H4K20me3 predicts a bad prognosis for patients with early stage adenocarcinoma. Altogether, our results highlight the role of chromatin disorders in lung carcinogenesis and support the idea that posttranslational modifications of histone H4 are relevant steps in the lung transformation process.
It is becoming clear that aberrant modification of histones can play a major role during the multistep process of cancer development. In this study we show that human lung tumors display a clear downregulation of H4K20 trimethylation. As loss of H4K20 trimethylation has been reported in lymphoma, colon and breast cancer as well as in various cancer cell lines (14, 15) , our results are consistent with the notion that aberrant H4K20me3 is a common hallmark of human cancer. Adenocarcinoma and squamous carcinoma are the main histological subtypes of non-small-cell lung cancer. They can be distinguished not only on the basis of pathological features but also by distinct molecular alterations that contribute to their development. This is best illustrated by the quite selective occurrence of Ras and EGFR mutations in adenocarcinoma (5) . In this study, we demonstrate that aberrant H4K20 trimethylation is frequent in squamous carcinoma and occurs early in preneoplastic precursors lesions in which the level of H4K20me3 strongly decreases along the sequential progression from cell hyperplasia to metaplasia, dysplasia and then to carcinome in situ. In contrast, whereas altered trimethylation of H4K20 is less frequent in adenocarcinoma, it was found to influence the disease outcome. Altogether, these data support the idea that aberrant trimethylation of H4K20 might play a role in the early steps of squamous carcinoma development, whereas it could contribute to the progression and aggressivity of adenocarcinoma. However, we have not excluded the possibility that atypical adenomatous hyperplasia, the precursors lesions of adenocarcinoma with bronchioloalveolar features, display loss of H4K20 trimethylation. These lesions are not available in frozen lung tissue, a requirement for our antibody performance.
The mechanism involved in the loss of H4K20me3 is not yet elucidated. Two histone methyltransferases (HMTases), namely Suv4-20h1/2, are responsible for H4K20 trimethylation (22) . Importantly, we demonstrate that loss of H4K20me3 is associated with a decrease of Suv4-20h2 transcripts. These data suggest that disruption of Suv4-20h2 expression might contribute to altered H4K20me3 pattern at least in lung tumors. Although we cannot exclude the possibility that yet unidentified demethylase(s) specific for H4K20me3 might be abnormally expressed in cancer cells, it is important to notice that similar correlation between H4K20me3 and Suv4-20h2 expression has been previously reported in human breast cancer cell lines as well as in a model of hepatocarcinogenesis induced by methyl deficiency in rats (1, 15) .
Approximately 45% of all lung carcinoma are limited to the chest, where surgical resection is not only an important therapeutic modality, but in many cases, the most effective method to control the disease. However, surgical treatment might not be sufficient or curative for a proportion of patients with NSCLC and especially adenocarcinoma, as inferred from 30% death within 5 years after surgery at stage I. Adjuvant chemotherapy is presently considered as a standard of care since beneficial effects have been demonstrated in stages IIA to IIIA (23) . However, some controversies still exist over the impact of adjuvant chemotherapy in stage IB (24, 25) . Based on a gene expression profile called the lung metagene model, Potti et al has identified a subgroup of patients with stage IA disease who were at high risk for recurrence (26) , thereby indicating that stage I NSCLC might represent heterogeneous prognostic subgroups. Recently, acetylation of H3K9 was reported to predict outcome of patients with stage I adenocarcinoma (27) . In this study we demonstrate that loss of histone H4K20 trimethylation correlates with a poor survival for stage I adenocarcinoma patients. Altogether these data indicate that histone modifications might represent useful genomic tools to identify prognostic subgroups of patients that could justify the use of adjuvant chemotherapy, and suggest that analysis of combined histone modifications may help to better define prognostic subgroups. Further prospective studies are now required to evaluate their predictive power to chemosensitivity. 
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